Marcio Souza, Praxis CEO
June 6, 2022 10:39 AM EDT
R&D

Prax­is nose­dives as an­ti­de­pres­sant ef­fort col­laps­es in PhII/III fail — lay­offs to fol­low

Max Gelman

Senior Editor

Prax­is shares $PRAX are tak­ing a tum­ble Mon­day af­ter the com­pa­ny re­port­ed its lead de­pres­sion drug failed a Phase II/III study, forc­ing a sub­stan­tial pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times